Nucleolar Sik-Similar Protein (Sik-SP) Is Required for the Maintenance of Uterine Estrogen Signaling Mechanism Via ERα

por Chung, Daesuk, Gao, Fei, Ostmann, Alicia, Hou, Xiaonan, Das, Sanjoy K.
Publicado 2012

Bip Is a Molecular Link between the Phase I and Phase II Estrogenic Responses in Uterus

por Ray, Sanhita, Hou, Xiaonan, Zhou, Han-E., Wang, Haibin, Das, Sanjoy K.
Publicado en Mol Endocrinol (2006)

Canonical Wnt Signaling Is Critical to Estrogen-Mediated Uterine Growth

por HOU, XIAONAN, TAN, YI, LI, MEILING, DEY, SUDHANSU K., DAS, SANJOY K.
Publicado en Mol Endocrinol (2004)

Synthesis of Reusable Silica Nanosphere-Supported Pt(IV) Complex for Formation of Disulfide Bonds in Peptides

por Hou, Xiaonan, Zhao, Xiaowei, Zhang, Yamei, Han, Aiying, Huo, Shuying, Shen, Shigang
Publicado en Molecules (2017)

Conventional Chemotherapy and Oncogenic Pathway Targeting in Ovarian Carcinosarcoma Using a Patient-Derived Tumorgraft

por Glaser, Gretchen, Weroha, S. John, Becker, Marc A., Hou, Xiaonan, Enderica-Gonzalez, Sergio, Harrington, Sean C., Haluska, Paul
Publicado en PLoS One (2015)

LY2157299 Monohydrate, a TGF-βR1 Inhibitor, Suppresses Tumor Growth and Ascites Development in Ovarian Cancer

por Zhang, Qing, Hou, Xiaonan, Evans, Bradley J., VanBlaricom, Jamison L., Weroha, Saravut J., Cliby, William A.
Publicado en Cancers (Basel) (2018)

Cyclin G1 and Cyclin G2 Are Expressed in the Periimplantation Mouse Uterus in a Cell-Specific and Progesterone-Dependent Manner: Evidence for Aberrant Regulation with Hoxa-10 Defic...

por Yue, Limin, Daikoku, Takiko, Hou, Xiaonan, Li, Meiling, Wang, Haibin, Nojima, Hiroshi, Dey, Sudhansu K., Das, Sanjoy K.
Publicado en Endocrinology (2005)

Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer

por Becker, Marc A., Hou, Xiaonan, Tienchaianada, Piyawan, Haines, Brian B., Harrington, Sean C., Weroha, S. John, Sathyanarayanan, Sriram, Haluska, Paul
Publicado en BMC Cancer (2016)

Targeting HER2 in patient‐derived xenograft ovarian cancer models sensitizes tumors to chemotherapy

por Harris, Faye R., Zhang, Piyan, Yang, Lin, Hou, Xiaonan, Leventakos, Konstantinos, Weroha, Saravut J., Vasmatzis, George, Kovtun, Irina V.
Publicado en Mol Oncol (2018)

Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A

por Torres, Diogo, Hou, Xiaonan, Bale, Laurie, Heinzen, Ethan P., Maurer, Matthew J., Zanfagnin, Valentina, Oberg, Ann L., Conover, Cheryl, Weroha, S. John
Publicado en PLoS One (2019)

Dual HER/VEGF receptor targeting inhibits in vivo ovarian cancer tumor growth

por Becker, Marc A., Farzan, Thahir, Harrington, Sean C., Krempski, James W., Weroha, S. John, Hou, Xiaonan, Kalli, Kimberly R., Wong, Tai W., Haluska, Paul
Publicado 2013

IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors

por Becker, Marc A., Hou, Xiaonan, Harrington, Sean C., Weroha, S. John, Gonzalez, Sergio E., Jacob, Kristina A., Carboni, Joan M., Gottardis, Marco M., Haluska, Paul
Publicado 2012

Prevention of Human Lymphoproliferative Tumor Formation in Ovarian Cancer Patient-Derived Xenografts()()

por Butler, Kristina A., Hou, Xiaonan, Becker, Marc A., Zanfagnin, Valentina, Enderica-Gonzalez, Sergio, Visscher, Daniel, Kalli, Kimberly R., Tienchaianada, Piyawan, Haluska, Paul, Weroha, S. John
Publicado en Neoplasia (2017)

HER receptor signaling confers resistance to the insulin-like growth factor 1 receptor inhibitor, BMS-536924

por Haluska, Paul, Carboni, Joan M., Eyck, Cynthia Ten, Attar, Ricardo M., Hou, Xiaonan, Yu, Chunrong, Sagar, Malvika, Wong, Tai W., Gottardis, Marco M., Erlichman, Charles
Publicado 2008

Gene expression differences between matched pairs of ovarian cancer patient tumors and patient-derived xenografts

por Liu, Yuanhang, Chanana, Pritha, Davila, Jaime I., Hou, Xiaonan, Zanfagnin, Valentina, McGehee, Cordelia D., Goode, Ellen L., Polley, Eric C., Haluska, Paul, Weroha, S. John, Wang, Chen
Publicado en Sci Rep (2019)

ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancer

por Kanakkanthara, Arun, Huntoon, Catherine J., Hou, Xiaonan, Zhang, Minzhi, Heinzen, Ethan P., O’Brien, Daniel R., Oberg, Ann L., John Weroha, S., Kaufmann, Scott H., Karnitz, Larry M.
Publicado en Nat Commun (2019)

Dual IGF-1R/InsR Inhibitor BMS-754807 Synergizes with Hormonal Agents in Treatment of Estrogen-Dependent Breast Cancer

por Hou, Xiaonan, Huang, Fei, Macedo, Luciana F., Harrington, Sean C., Reeves, Karen A., Greer, Ann, Finckenstein, Friedrich Graf, Brodie, Angela, Gottardis, Marco M., Carboni, Joan M., Haluska, Paul
Publicado 2011

Pharmacokinetics of endoxifen and tamoxifen in female mice: implications for comparative in vivo activity studies

por Reid, Joel M., Goetz, Matthew P., Buhrow, Sarah A., Walden, Chad, Safgren, Stephanie L., Kuffel, Mary J., Reinicke, Kathryn E., Suman, Vera, Haluska, Paul, Hou, Xiaonan, Ames, Matthew M.
Publicado en Cancer Chemother Pharmacol (2014)

Geminin facilitates FoxO3 deacetylation to promote breast cancer cell metastasis

por Zhang, Lei, Cai, Meizhen, Gong, Zhicheng, Zhang, Bingchang, Li, Yuanpei, Guan, Li, Hou, Xiaonan, Li, Qing, Liu, Gang, Xue, Zengfu, Yang, Muh-hua, Ye, Jing, Chin, Y. Eugene, You, Han
Publicado en J Clin Invest (2017)

Transcriptomic Characterization of Endometrioid, Clear Cell, and High Grade Serous Epithelial Ovarian Carcinoma

por Fridley, Brooke L., Dai, Junqiang, Raghavan, Rama, Li, Qian, Winham, Stacey J., Hou, Xiaonan, Weroha, S. John, Wang, Chen, Kalli, Kimberly R., Cunningham, Julie M., Lawrenson, Kate, Gayther, Simon A., Goode, Ellen L.
Publicado en Cancer Epidemiol Biomarkers Prev (2018)